David Heredia Sierra, MD
Interventional Cardiology · Cayey, PRNPI 1700293990
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,628 of the $8,383 with a category attached, or 79.1%. 22 manufacturers reported payments, led by Biotronik Inc. at 29.6% of the total. Reporting peaked in 2019 at $4,102 and has fallen 86.7% since, to $547 in 2025. That places this record below the midpoint for interventional cardiology clinicians in PR, where the typical reported total is $12,032.
Across 252 payments — averaging $33.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$2K
- Boston Scientific$1K
- Medtronic$1K
- Abbott$874
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$489
- Johnson & Johnson$294
- plus $2K from 16 others
What the payments were for
- Travel & lodging$1,67220%
- Food & beverage$6,62879%
- Gifts$841%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik Inc. | 13 | $2,483 |
| Boston Scientific | 67 | $1,424 |
| Medtronic(2 entities) | 36 | $1,057 |
| Abbott | 28 | $874 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 47 | $489 |
| Johnson & Johnson | 15 | $294 |
| AstraZeneca | 10 | $266 |
| Amgen | 4 | $223 |
| Philips North America LLC | 2 | $195 |
| Novartis | 2 | $157 |
| Abiomed | 1 | $144 |
| PBG Puerto Rico LLC | 10 | $131 |
| Johnson And Johnson International | 1 | $120 |
| E.r. Squibb & Sons, L.L.C. | 5 | $115 |
| Edwards Lifesciences | 1 | $100 |
| Bayer | 1 | $97 |
| Chiesi USA, Inc. | 1 | $84 |
| Cardinal Health P.r. 120 Inc | 4 | $50 |
| Boehringer Ingelheim | 1 | $24 |
| Cordis US CORP. | 1 | $23 |
| Merck | 1 | $20 |
| Pfizer Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$216
- OPTIS$157
- HawkOne$145
- Impella$144
- Carto 3$120
- (4067) Tack Endovascular Systems BTK$115
- Watchman$103
- RESONATE$101
- Edwards SAPIEN 3 Transcatheter Heart Valve$100
How this compares
$8,383 in reported general payments places this provider in the 35th percentile of 39 interventional cardiology providers in Puerto Rico.
See all interventional cardiology providers in Puerto Rico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 121 | $137,782 |
| XareltoRivaroxaban | 123 | $122,589 |
| EntrestoSacubitril/Valsartan | 76 | $93,416 |
| JardianceEmpagliflozin | 12 | $9,787 |
| FarxigaDapagliflozin Propanediol | 15 | $8,813 |
| Metoprolol Succinate | 250 | $3,401 |
| Ranolazine ErRanolazine | 34 | $3,067 |
| ClopidogrelClopidogrel Bisulfate | 191 | $2,133 |
| Nifedipine ErNifedipine | 124 | $2,125 |
| Losartan Potassium | 236 | $1,969 |
| Candesartan Cilexetil | 38 | $1,948 |
| Amlodipine Besylate | 248 | $1,477 |
| Lisinopril | 143 | $1,107 |
| Rosuvastatin Calcium | 84 | $1,081 |
| Hydralazine Hcl | 77 | $1,075 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $294 | $122,589123 claims |
| NovartisEntresto | $157 | $93,41676 claims |
| Boehringer IngelheimJardiance | $24 | $9,78712 claims |
| AstraZenecaFarxiga | $266 | $8,81315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 39 interventional cardiology providers in Puerto Rico.
Other interventional cardiology in Cayey
- Damian Grovas AbadSan Juan$498K
- Eric Carro JimenezSan Juan$416K
- Hector Martinez GonzalezMayaguez$261K
- Alejandro Lopez MasPonce$142K
- Ricardo SantiagoManati$131K
- Edwin I Perez MarreroSan Juan$129K
- Pedro Colon HernandezCaguas$128K
- Enrique Hernandez VilaPonce$44K
- Ismael Ortiz-CartagenaBayamon$40K
- Bayoan Ramos ParraCaguas$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.